Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors
Open Access
- 5 February 2024
- Vol. 9 (2) , 102217
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Pfizer
This publication has 52 references indexed in Scilit:
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyThe Lancet Oncology, 2016
- Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemiaBlood, 2016
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience, 2016
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian CancerCancer Immunology Research, 2015
- Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibitionOncotarget, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the PromisingFrontiers in Oncology, 2014
- Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM -Defective TumorsScience Translational Medicine, 2013
- Playing the End Game: DNA Double-Strand Break Repair Pathway ChoiceMolecular Cell, 2012
- The DNA-damage response in human biology and diseaseNature, 2009